Autoimmune Pancreatitis in the USA



Fig. 28.1
Rates of relapse in type 1 and type 2 AIP. Kaplan-Meier survival curves for relapse-free survival following diagnosis for type 1 AIP (red line) compared to type 2 AIP (blue line) are shown. Relapse-free survival is significantly longer in those with type 2 AIP (p < 0.001, using Wilcoxon test)






Profile of AIP in the USA


The profile of AIP patients in the Mayo Clinic cohort is presented in Table 28.1. A comparison to the profile of AIP cohorts from across the world, performed in an international survey [62], is presented in detail in the previous chapter.


Table 28.1
Clinical profile of type 1 and type 2 AIP









































































































































Variable

Type 1 AIP (n = 116)

Type 2 AIP (n = 44)

p value

Age at diagnosis, mean (SD)

63.4 (13.3)

37.0 (19.2)

<0.01a

Male gender, n (%)

93 (80.2)

26 (59.1)

<0.01

Presenting symptoms:

 Jaundice

75 (64.7)

18 (40.9)

<0.01

 Pancreatic mass

48 (41.4)

14 (31.8)

0.27

 Pancreatitis

13 (11.2)

24 (54.5)

<0.01

 Others

8 (6.9)

2 (4.5)

0.72b

Serum IgG4 status:

 >ULN, n (%)

71/99 (71.7)

2/33 (6.1)

<0.01

 >2xULN, n (%)

41/99 (41.4)

0/33

<0.01

Parenchymal imaging at presentation:

 Diffuse enlargement

49 (30.6)

11 (25.0)

0.04

 Focal enlargement

20 (17.2)

6 (13.6)

0.64b

 Indeterminate (includes atypical)

27 (23.3)

23 (52.3)

<0.01

 N/A

20 (17.2)

4 (9.1)
 

Biliary involvement at presentation:

 Distal only

54 (46.7)

20 (45.4)

0.90

 Proximal ± distal

30 (25.9)


<0.01b

 None

32

24

<0.01

Other organ involvement (excluding IBD)

58 (50.4)

0

<0.01

# of relapses per patient:
   

 0

63

40
 

 1

35

4
 

 ≥2

18

0
 

Duration of initial prednisone course, median (IQR)

2.8, 2.3–4.6

2.8, 2.1–3.1

0.94

Duration of f/u, months (SD)

57.3 (48.8)

75.9 (11.3)

0.13

Duration of f/u, years (SD)

4.8 (4.1)

6.3 (6.2)

0.13


Data of patients in the Mayo Clinic Rochester cohort of AIP patients (1986–2013) are presented here. All data are displayed as n (%), unless otherwise indicated. Comparisons are performed using chi-squared test, unless otherwise indicated

aComparison using the paired t-test

bComparisons using Fisher’s exact t-test


Clinical Practices Regarding AIP in the USA


In this section, we summarize the salient differences in clinical practices regarding diagnosis and management of AIP in the USA as compared to Asian/Japanese strategy described in separate chapters in this book.


Diagnosis of AIP


One important difference in the diagnosis strategy lies in the utility of pancreatic core biopsies. EUS-guided pancreatic core biopsies are routinely performed at our center [63] and have also been routinely done at many other centers in the USA [64]. These are included in the HISORt criteria [28, 36]. In contrary, core biopsies are not performed frequently in Japan and thereby not required in the Asian and Japanese criteria [6, 34].

Another major contention is in the use of ductal imaging (ERP/MRP). The HISORt criteria [28, 36] does not require for ERP/MRP, while the Asian and Japanese criteria require pancreatic duct imaging by ERP/MRP [6, 34]. In the USA, routine ERP/MRP is not performed of obstructive jaundice. The diagnostic utility of ERP from the diagnosis of AIP and differentiating it from pancreatic cancer in the USA was not satisfactory in contrary to that observed in the Japanese centers [65].

The ICDC [40] includes ERP as an additional option which could supplement evidence in favor of AIP to qualify patients for a steroid trial who would otherwise need to be subjected to core biopsy. This is applicable to patients who do not have highly supportive parenchymal imaging and have some collateral evidence (other organ involvement or serum IgG4 elevations) but not sufficient for meeting criteria [40]. In our experience, only 10 % of patients would fall in this category who could be subjected to ductal imaging or core biopsy for diagnosis by ICDC thereby allowing for regional flexibility. About 20 % of patients do not have any collateral evidence and histological diagnosis is mandated in these patients regardless of parenchymal or ductal imaging.


Treatment and Follow-Up of AIP


Our protocol for initial steroid treatment is as follows: prednisone 40 mg/day for 4 weeks and tapering off by 5 mg/week to complete a course of 11 weeks. Treatment response is objectively monitored by clinical follow-up, follow-up imaging, and biochemical tests (LFT). Steroid taper is started once response to treatment is confirmed objectively [59, 60].

In our experience, about half of type 1 AIP patients do not relapse after short course of steroid treatment [60]. No maintenance therapy is necessary in these patients [60]. The major difference from Asian strategy is the need for maintenance steroid therapy [66]. Centers in Japan routinely use a prolonged maintenance therapy for up to 3 years with the logic that most patients relapse within 3 years [66]. In a multicenter study from Japan, it was shown that maintenance therapy reduced the relapse rate to 23 % from 34 % in those who weaned off steroids [66]. In our experience, the risks of universal use of maintenance steroid therapy outweigh the benefits in AIP.

Our strategy for follow-up for relapses involves close monitoring of symptoms with radiological and biochemical confirmation of relapse if symptomatic [60]. Early detection of relapses and prompt institution of treatment are recommended. Steroid retreatment with or without immunomodulators, rituximab treatment, and maintenance therapy with these agents may be necessary in 30–40 % of AIP patients with frequent relapses or refractory disease or steroid intolerance [60]. Details of treatment of relapses and maintenance therapy options are discussed extensively in an earlier chapter.


Conclusion


AIP is a fibroinflammatory disease affecting the pancreas which has recently been characterized. We have described the historical aspects, clinical profile, and practice patterns regarding AIP in the USA.


References



1.

Sarles H, Sarles JC, Muratore R, et al. Chronic inflammatory sclerosis of the pancreas – an autonomous pancreatic disease? Am J Dig Dis. 1961;6:688–98.PubMedCrossRef


2.

Sarles H, Sarles JC, Camatte R, et al. Observations on 205 confirmed cases of acute pancreatitis, recurring pancreatitis, and chronic pancreatitis. Gut. 1965;6(6):545–59.PubMedCentralPubMedCrossRef


3.

Sarles H, Adler G, Dani R, et al. The pancreatitis classification of Marseilles-Rome 1988. Scand J Gastroenterol. 1989;24(6):641–2.PubMedCrossRef


4.

Yoshida K, Toki F, Takeuchi T, et al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. 1995;40(7):1561–8.PubMedCrossRef


5.

Ectors N, Maillet B, Aerts R, et al. Non-alcoholic duct destructive chronic pancreatitis. Gut. 1997;41(2):263–8.PubMedCentralPubMedCrossRef


6.

Society MotCCfAPotJP. Diagnostic criteria for autoimmune pancreatitis by the Japan Pancreas Society. J Jpn Pancreas Soc. 2002;17:585–7.


7.

Uchida K, Okazaki K, Konishi Y, et al. Clinical analysis of autoimmune-related pancreatitis. Am J Gastroenterol. 2000;95(10):2788–94.PubMedCrossRef


8.

Okazaki K, Uchida K, Ohana M, et al. Autoimmune-related pancreatitis is associated with autoantibodies and a Th1/Th2-type cellular immune response. Gastroenterology. 2000;118(3):573–81.PubMedCrossRef

Only gold members can continue reading. Log In or Register to continue

Jun 3, 2017 | Posted by in GENERAL SURGERY | Comments Off on Autoimmune Pancreatitis in the USA
Premium Wordpress Themes by UFO Themes
%d bloggers like this: